Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile

Abstract

Introduction Inhaled corticosteroid/long-acting β 2 -adrenoceptor agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination (FDC) is currently recommended as controller option at asthma Step 4 and as preferred treatment at asthma Step 5, but no research investigated the potential drawbacks of this therapeutic option in a large asthmatic population. Thus, the aim of this study was to quantify the potential drawbacks of triple FDC therapy in asthma. Methods A pairwise meta-analysis was performed according to PRISMA-P guidelines to assess the risk of overall serious adverse events (SAEs), cardiovascular SAEs, and pneumonia reported as SAE in asthmatic patients treated with ICS/LABA/LAMA FDC vs ICS/LABA FDC. A pooled analysis was performed to calculate the frequency of SAEs. Results Data from 7204 asthmatic patients were extracted from the CAPTAIN, IRIDIUM, TRIMARAN, and TRIGGER studies. Triple FDC vs ICS/LABA FDC did not increase the risk of total SAEs (RR 0.99 95% CI 0.83–1.18) and cardiac SAEs (RR 0.74 95% CI 0.39–1.40), whereas the sensitivity analysis performed to resolve heterogeneity resulted in increased risk of vascular SAEs (RR 3.23 95% CI 1.05–9.90, P<0.05). The level of ICS dose did not modulate the risk of pneumonia, in any case pneumonia was the most frequent SAE (0.57%). These results were not affected by significant risk of bias. Conclusion Triple FDC is a safe pharmacological therapy in severe asthmatic patients; it is characterized by a favourable safety profile and few potential drawbacks, namely, the increased risk of vascular SAEs, that certainly are worthy of future investigations.

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma

“…From a clinical point of view, it is not possible to check if BNT162b2 may really elicit a greater risk of bronchospasm compared to a placebo because, unexpectedly, the key sponsored phase 3 RCT on BNT162b2 (NCT04368728, NCT04713553, NCT04816669), although already completed and/or published in MEDLINE, reported no results posted in the ClinicalTrial.gov database [ 63 , 64 ]. This is a missing opportunity to assess the real safety profile concerning serious adverse events of BNT162b2 via pooled analysis, as already demonstrated in other scientific contexts [ 65 , 66 ]. Therefore, unbiased and well performed observational studies may help to solve this matter and confirm the findings of our research.…”

Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement

“…The main limitations to this study are intrinsic to the quantitative synthesis methods, which are based on large sample approximations, and to the intrinsic weakness of the included studies. 62 , 63 Indeed, most of the studies were post-hoc analyses of RCTs, and only one was an RCT prospectively assessing the CID composite endpoint. Moreover, the studies spanned a duration ranging from 3 to 48 months, introducing a certain level of temporal heterogeneity that could potentially act as an effect modifier, suggesting greater efficacy of pharmacological treatment in shorter-term studies.…”

Inhaled Treatments for Bronchial Asthma: Molecules and Devices

“…Finally, two triple fixed-dose combinations are approved for asthma (ICS+LABA+LAMA) [26][27][28][29] :…”